Pseudomonas Aeruginosa Pneumonia In Immunocompromised Host: Treatment With Ceftazidime Plus Amikacin

In order to evaluate efficacy and tolerability of ceftazidime + amikacin in the treatment of Pseudomonas aeruginosa pneumonia in immunocompromised hosts, we enrolled all the patients admitted to our ward from January 1995 until June 1995 with this pathology. The dose regimen of ceftazidime + amikacin was 2 g x 3 i.v./die + 1 g i.v./die for 30 days and the first 10 days, respectively. Overall we treated 12 patients (9 with HIV infection). Eight out of them had a complete response to treatment, 4 did not respond. All non-responder patients had HIV infection. We observed 3 relapses in a mean time of 3.8 +/- 1.6 months. No severe side effects were observed during the treatment period. Ceftazidime + amikacin is an effective therapeutic association for Pseudomonas aeruginosa pneumonia in immunocompromised hosts, including subjects with HIV infection.